Skip to content

The effect of intravenous equivalent dose of phenylephrine and norepinephrine on fetal umbilical artery pH in women with severe eclampsia undergoing cesarean delivery with spinal anesthesia

The effect of intravenous equivalent dose of phenylephrine and norepinephrine on fetal umbilical artery pH in women with severe eclampsia undergoing cesarean delivery with spinal anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047529
Enrollment
Unknown
Registered
2021-06-20
Start date
2021-06-21
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension in women with severe eclampsia undergoing caesarean section

Interventions

phenylephrine group:use phenylephrine when hypotension happens
norepinephrine group:use norepinephrine when hypotension happens

Sponsors

Women's Hospital, School of Medicine, Zhengjiang University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 40 years; 2.ASA class II or III; 3.Singleton pregnancy patients with severe eclampsia. Severe eclampsia was defined as systolic blood pressure >=160mmHg and/or diastolic blood pressure >=110mmHg (bed rest, at least 4 hours between blood pressure measurements); Or (1) thrombocytopenia (platelets <100x10^9 / L); (2)Liver function damage (serum transaminase level is more than 2 times the normal value); (3)Renal impairment (serum creatinine increased more than 1.1mg/dL or more than 2 times the normal value); 4.New onset cerebral or visual disturbances.

Exclusion criteria

Exclusion criteria: 1.Any contraindication to spinal anesthesia; 2.Active labor; 3.Placenta previa or other placenta abnormalities; 4.Multiple pregnancy; 5.Pulmonary edema; 6.Allergy to phenylephrine and norepinephrine; 7.Umbilical cord prolapse; 8.kKnown fetal abnormalities; 9.Less than 28 weeks gestation; 10.Refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
umbilical artery PH value;

Secondary

MeasureTime frame
umbilical vein PH value;heart stroke;maternal outcomes (nausea and vomiting; bradycardia; tachycardia; hypertension; dizzy; dyspnea);Other non-invasive hemodynamic parameters except cardiac displacement;stroke volume;systemic vascular resistance;

Countries

China

Contacts

Public ContactQian Xiaowei

Women's Hospital, School of Medicine, Zhengjiang University

qianxw@zju.edu.cn+86 15700157161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026